Results 281 to 290 of about 9,077,301 (404)

Super‐Refractory Status Epilepticus (SRSE) in a Patient With Compound Heterozygous OPA1 Variants: Case Report and Literature Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Super‐Refractory Status Epilepticus (SRSE) is a rare, life‐threatening neurological emergency with unclear etiology in many cases. Mitochondrial dysfunction, often due to disease‐causing genetic variants, is increasingly recognized as a cause, with each gene producing distinct pathophysiological mechanisms.
Pouria Mohammadi, Lara Basovic, Christopher Michael McGraw   +2 more
wiley   +1 more source

Premarket and postmarket real-world evidence studies supporting U.S. Food and Drug Administration regulatory decision-making, 2016-2024. [PDF]

Clin Trials
Li LY, Ramachandran R, Ross JS, Wallach JD.   +3 more
europepmc   +1 more source

Referee report. For: Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: A pilot trial in four villages of Eastern Myanmar [version 1; referees: 1 approved]

, 2017
Rick M. Fairhurst
openalex   +1 more source

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein, Maximilian Mönch, Meret Herdick, Frauke Stascheit, Sarah Hoffmann, Hannah Preßler, Philipp Mergenthaler, Carla Dusemund, Paolo Doksani, Haoqi Sun, Pushpa Narayanaswami, Andreas Meisel, Lea Gerischer, Sophie Lehnerer   +13 more
wiley   +1 more source

Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications

Blood Advances, 2018
E. Dianne Pulte, Lei Nie, Nicole Gormley, Kirsten B. Goldberg, Amy McKee, Ann Farrell, Richard Pazdur   +6 more
doaj   +1 more source

Beyond business as usual for lymphatic filariasis mass drug administration in hotspot districts. [PDF]

Int Health
de Souza DK, Sumboh JG, Laryea NA, Asiedu O, Alomatu B, Mensah SK, Otchere J, Opare JL, Ahorlu CS.   +8 more
europepmc   +1 more source

Under-reporting of Adverse Drug Reactions to the Food & Drug Administration

, 2018
James Alexander Lamb
openalex   +1 more source

Predicting Loss of Ambulation in Limb Girdle Muscular Dystrophy R9

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Limb girdle muscular dystrophy type R9 (LGMDR9) results from biallelic variants in FKRP. There is limited data to predict loss of ambulation (LOA) among those with LGMDR9. Methods Participants in an ongoing dystroglycanopathy natural history study (NCT00313677) with FKRP variants who had achieved ambulation and were more than 3 ...
Chandra L. Miller, Lauren N. Coffey, Shelley R. H. Mockler, Katie M. Laubscher, Carrie M. Stephan, M. Bridget Zimmerman, Katherine D. Mathews   +6 more
wiley   +1 more source

Coverage evaluation of mass drug administration for lymphatic filariasis in four endemic districts of Jharkhand, India. [PDF]

J Health Popul Nutr
Biswas B, Jahnavi G, Gupta P, Paul A, Varshney S.   +4 more
europepmc   +1 more source